Followers | 83 |
Posts | 36201 |
Boards Moderated | 0 |
Alias Born | 03/09/2010 |
![](https://investorshub.advfn.com/uicon/193357.png?cb=1469016413)
Monday, December 15, 2014 2:57:33 PM
First, Amgen did not really pay 1 Billion $ fot Tvec- they bought Biovex for $425M in cash (note Biovex had more than one interesting vaccine program). The rest of it is what we call Biotech dollars- the headline value is exciting, but what actually gets paid out reamian to be seen.
Second, the danger in these sorts of cross study and cross drug comparisons is well know to biotech investors. Although I agree with many of your points, I believe the major weakness is comparing p2 data to p3 data in over 400 patients. In addition, comparisons of Yervoy+Tvec etc are risky as Yervoy a CTLA-4 inhibitor is a diferent mechanism of action vs PD-1
Finally, I do not think the case was made strongly for valuation of ONCS. If the point is, it could hit big, just like Tvec, then I would say yes I agree, but .........
It will be interesting to compare the protocols for the PD-1/Immunopulse vs PD-1/Tvec trials.
And life flows on Within You and Without You
Recent ONCSQ News
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 07:30:19 PM
Glidelogic Corp. Announces Revolutionary AI-Generated Content Copyright Protection Solution • GDLG • Jul 26, 2024 12:30 PM
Southern Silver Files NI43-101 Technical Report for its Updated Preliminary Economic Assessment for the Cerro Las Minitas Project • SSV • Jul 25, 2024 8:00 AM
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM